Avantor, Inc. reports developments as a life science tools company supplying mission-critical products and services to life sciences and advanced technology customers through its VWR Distribution & Services and Bioscience & Medtech Products businesses. Recurring updates cover earnings, cash flow, leverage, guidance, segment performance and the company’s Revival transformation program, including VWR brand activity, manufacturing and supply-chain improvements and e-commerce upgrades.
Company news also covers portfolio and infrastructure actions such as Masterflex fluid handling systems, single-use assemblies, peristaltic pumps, J.T. Baker high-purity process chemicals, and expanded microbial and stability testing capabilities for regulated biopharma manufacturing. Governance and management updates include finance leadership changes and appointments tied to bioscience, medtech products and enterprise transformation.
Avantor (NYSE: AVTR) reported third-quarter 2026 sales of $1,698.3 million, returning to year-over-year growth and raising parts of its full-year outlook. Sales rose 4.6%, with organic growth, excluding currency effects, of 5.2%. Net income was $203.4 million versus a $711.8 million loss a year earlier; diluted GAAP earnings per share were $0.30 versus a $1.04 loss. Adjusted earnings per share were $0.22.
VWR Distribution & Services sales rose 5.0%, but segment adjusted operating income declined. Bioscience & Medtech Products sales rose 3.5%, with higher adjusted operating income. Quarterly operating cash flow was $195.1 million and free cash flow was $156.2 million. Avantor now expects 2026 organic revenue growth of 0.75%–1.25%, adjusted earnings per share of $0.81–$0.83 and free cash flow of $525 million–$550 million, excluding cash restructuring costs. Its adjusted EBITDA margin outlook remains 14.8%–15.3%.
Avantor (NYSE: AVTR) has appointed Mikey Santiago as Chief Information Officer to lead the company's global information technology strategy. His responsibilities include advancing Avantor's digital transformation agenda and supporting customer experience and operations.
Santiago brings more than two decades of technology leadership experience, including serving as a four-time CIO and holding senior leadership roles at Danaher and its operating companies. His experience includes acquisition integrations, cloud modernization, cybersecurity, advanced analytics and artificial intelligence.
Avantor (AVTR) will release its third quarter 2026 financial results before the market opens on October 28, 2026. A related conference call will take place that day at 8:00 a.m. Eastern Time. A live audio webcast will be accessible through the News & Events page in the Investor section of Avantor's website, with a replay available for 30 days.
Avantor (AVTR) has appointed Todd Garner as Executive Vice President and Chief Financial Officer, effective September 21, 2026. He will lead the company’s global finance organization, covering financial planning and analysis, accounting, treasury, tax, investor relations and internal audit.
Garner previously served as Executive Vice President and Chief Financial Officer of CONMED Corporation from 2018 to 2026 and has more than 30 years of finance, operational and public company leadership experience, including leadership roles at C. R. Bard. Steve Eck, who has served as Interim CFO since June 24, 2026, will continue as Senior Vice President and Chief Accounting Officer.
Avantor (NYSE: AVTR) reported second quarter 2026 net sales of $1,692.3 million, up 0.5% year over year, with a 0.4% organic decline after a 0.9% positive FX impact. Net income fell to $38.1 million, while adjusted net income was $143.3 million. Adjusted EBITDA reached $254.3 million with a 15.0% margin.
Operating cash flow was $178.2 million and free cash flow $142.8 million, supporting repayment of $112.1 million of debt and contributing to adjusted net leverage of 3.3x. The VWR Distribution & Services segment delivered 1.7% organic growth, while Bioscience & Medtech Products declined 5.6% organically.
Avantor raised its fiscal 2026 organic revenue growth outlook from -2.5%–-0.5% to -0.5%–+0.5% and increased adjusted EPS guidance to $0.80–$0.83 from $0.77–$0.83, while maintaining adjusted EBITDA margin guidance of 14.8%–15.3% and free cash flow guidance of $500–$550 million.
Avantor (NYSE: AVTR) announced that its NuSil brand has expanded its collaboration with the Population Council to support development of a new three-month dapivirine vaginal ring for HIV prevention. NuSil supplies high-purity medical-grade silicones used in the ring's drug-device combination design.
The collaboration builds on NuSil's prior role in supplying silicones for the approved one-month dapivirine vaginal ring, used in 12 sub-Saharan African countries for women aged 16 and older, including those breastfeeding. The new ring is designed to require only four rings per year, aiming to improve adherence, convenience, and affordability, especially in high-prevalence regions. According to the Population Council, the three-month ring was submitted to the European Medicines Agency in November 2025, and clinical studies have shown it delivers higher dapivirine levels than the monthly version, suggesting enhanced efficacy and user acceptability.
Avantor (NYSE: AVTR) will release its second quarter 2026 earnings before the U.S. market opens on Wednesday, July 29, 2026. Management will host a conference call at 8:00 a.m. EDT, with a live audio webcast and a 30-day replay available on the company’s investor website.
Avantor (NYSE: AVTR) appointed Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory, effective May 19, 2026. He will lead global quality assurance, quality systems, and regulatory affairs across all Avantor businesses.
Porreca previously led Quality and Regulatory at Getinge and held senior roles at Becton Dickinson, C.R. Bard, and Smith+Nephew. Avantor highlights his expertise in complex global regulatory environments as key to scaling operations and supporting life sciences and advanced technology customers.
Avantor (NYSE: AVTR) reported Q1 2026 results for the quarter ended March 31, 2026. Net sales were $1,581.4 million, flat year-over-year; organic sales declined 4.1%. Net income was $43.3 million (GAAP); adjusted net income was $114.0 million. Adjusted EBITDA was $219.4 million (13.9% margin). Diluted GAAP EPS was $0.06; adjusted EPS was $0.17. Operating cash flow was $58.7 million and free cash flow was $25.2 million. GAAP net leverage was (6.5x); adjusted net leverage was 3.3x. Segment highlights: VWR sales $1,150.0 million (organic -4.8%; adj. op income $105.4 million, 9.2% margin); Bioscience & Medtech sales $431.4 million (organic -2.0%; adj. op income $102.7 million, 23.8% margin). Company reaffirmed FY 2026 guidance and will host a conference call April 29, 2026 at 8:00 a.m. ET.
Avantor (NYSE: AVTR) appointed Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products (BMP) and Chief Transformation Officer, effective May 1, 2026. He will lead BMP growth, improve operational performance, and head the Revival Management Office to drive enterprise transformation. Benoit Gourdier will remain through end of 2026 to transition the role.